![](https://investorshub.advfn.com/uicon/27005.png?cb=1475899188)
Thursday, May 28, 2020 4:08:34 PM
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days". https://sapphirebiotech.com
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM